137 related articles for article (PubMed ID: 28835660)
1. The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer.
Sugimoto M; Takagi T; Konno N; Suzuki R; Asama H; Watanabe K; Nakamura J; Waragai Y; Kikuchi H; Takasumi M; Sato Y; Hikichi T; Ohira H
Sci Rep; 2017 Aug; 7(1):9198. PubMed ID: 28835660
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of serum cell death biomarkers for diagnosing biliary tract cancer.
Sugimoto M; Abe K; Hayashi M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Watanabe K; Nakamura J; Kikuchi H; Waragai Y; Takasumi M; Hashimoto M; Hikichi T; Nozawa Y; Ohira H
Sci Rep; 2018 Nov; 8(1):16997. PubMed ID: 30451962
[TBL] [Abstract][Full Text] [Related]
3. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
4. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP
Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875
[TBL] [Abstract][Full Text] [Related]
5. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
6. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer.
Kishimoto T; Eguchi H; Nagano H; Kobayashi S; Akita H; Hama N; Wada H; Kawamoto K; Tomokuni A; Tomimaru Y; Umeshita K; Doki Y; Mori M
Cancer Sci; 2013 Dec; 104(12):1626-31. PubMed ID: 24118467
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
8. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
9. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness and acceleratory effect of macrophage inhibitory cytokine-1 on biliary tract cancer: an experimental biomarker analysis.
Sugimoto M; Suzuki R; Nozawa Y; Takagi T; Konno N; Asama H; Sato Y; Irie H; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Suzuki O; Hashimoto Y; Hikichi T; Ohira H
Cancer Cell Int; 2022 Aug; 22(1):250. PubMed ID: 35948981
[TBL] [Abstract][Full Text] [Related]
12. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.
Matull WR; Andreola F; Loh A; Adiguzel Z; Deheragoda M; Qureshi U; Batra SK; Swallow DM; Pereira SP
Br J Cancer; 2008 May; 98(10):1675-81. PubMed ID: 18475301
[TBL] [Abstract][Full Text] [Related]
13. Serum macrophage inhibitory cytokine-1 serves as a novel diagnostic biomarker of early-stage colorectal cancer.
Dai C; Zhang X; Ma Y; Chen Z; Chen S; Zhang Y; Li M
Biomarkers; 2021 Nov; 26(7):598-605. PubMed ID: 34266319
[TBL] [Abstract][Full Text] [Related]
14. The value of macrophage inhibitory cytokine-1 level in differentiating benign from malignant solitary pulmonary nodules.
Xu CH; Xue JS; Zhang XW; Yu LK; Lin Y
Clin Respir J; 2018 Apr; 12(4):1473-1478. PubMed ID: 28834599
[TBL] [Abstract][Full Text] [Related]
15. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
16. A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC).
Ruzzenente A; Iacono C; Conci S; Bertuzzo F; Salvagno G; Ruzzenente O; Campagnaro T; Valdegamberi A; Pachera S; Bagante F; Guglielmi A
Surgery; 2014 Apr; 155(4):633-9. PubMed ID: 24468034
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
[TBL] [Abstract][Full Text] [Related]
18. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.
Kikkawa S; Sogawa K; Satoh M; Umemura H; Kodera Y; Matsushita K; Tomonaga T; Miyazaki M; Yokosuka O; Nomura F
Int J Proteomics; 2012; 2012():108609. PubMed ID: 22888427
[TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
